Physiomics PLC Dispatch of Annual Report and Notice of AGM (4118Q)
21 Octubre 2019 - 1:00AM
UK Regulatory
TIDMPYC
RNS Number : 4118Q
Physiomics PLC
21 October 2019
21 October 2019
Physiomics plc
("Physiomics") or (the "Company")
Dispatch of Annual Report and Notice of AGM
Physiomics plc (AIM: PYC), a provider of technology-based
solutions to predict the effects of cancer treatment regimens, is
pleased to announce that it has today posted to shareholders its
Annual Report and Accounts for the financial year ended 30 June
2019 together with its Notice of Annual General Meeting
("AGM").
As previously announced on the 30 September 2019, the Company's
AGM will be held at 10.00 a.m. on 19 November 2019 at the Company's
registered office, The Magdalen Centre, Oxford Science Park, Robert
Robinson Avenue, Oxford, OX4 4GA.
A copy of the Notice of AGM, containing further details of the
resolutions, as well as a copy of the Company's Annual Report and
Accounts will be made available today on the Company's website at
www.physiomics.co.uk/investors/reports-prospectus/.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0)20 3764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry. The Company's Virtual Tumour(TM) technology
uses computer modelling to predict the effects of cancer drugs and
treatments to improve the success rate of drug discovery and
development projects while reducing time and cost. The predictive
capability of Physiomics' technologies have been confirmed by over
70 projects, involving over 30 targets and 60 drugs, and has worked
with clients such as Merck KGaA, Merck & Co, Bayer and
Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals that have attracted thousands of
citations.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCKMMMGGRNGLZM
(END) Dow Jones Newswires
October 21, 2019 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024